These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18227533)

  • 1. Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies?
    Kruskal JB
    Radiology; 2008 Feb; 246(2):339-40. PubMed ID: 18227533
    [No Abstract]   [Full Text] [Related]  

  • 2. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
    Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
    Forsberg F
    Radiology; 2010 Feb; 254(2):317-8. PubMed ID: 20093504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Science to practice: Will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced gray-scale US?
    Kruskal JB
    Radiology; 2006 Jul; 240(1):1-2. PubMed ID: 16793969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects.
    Palmowski M; Huppert J; Ladewig G; Hauff P; Reinhardt M; Mueller MM; Woenne EC; Jenne JW; Maurer M; Kauffmann GW; Semmler W; Kiessling F
    Mol Cancer Ther; 2008 Jan; 7(1):101-9. PubMed ID: 18202013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
    Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
    Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
    Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
    Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
    Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis.
    Rychak JJ; Graba J; Cheung AM; Mystry BS; Lindner JR; Kerbel RS; Foster FS
    Mol Imaging; 2007; 6(5):289-96. PubMed ID: 18092513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.
    Wang J; Qin B; Chen X; Wagner WR; Villanueva FS
    Mol Pharm; 2017 Mar; 14(3):781-790. PubMed ID: 28165246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
    Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
    J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scoping Review of Targeted Ultrasound Contrast Agents in the Detection of Angiogenesis.
    Lau C; Rivas M; Dinalo J; King K; Duddalwar V
    J Ultrasound Med; 2020 Jan; 39(1):19-28. PubMed ID: 31237009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.
    Lim EH; Danthi N; Bednarski M; Li KC
    Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
    Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
    Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model.
    Xuan JW; Bygrave M; Valiyeva F; Moussa M; Izawa JI; Bauman GS; Klibanov A; Wang F; Greenberg NM; Fenster A
    Mol Imaging; 2009; 8(4):209-20. PubMed ID: 19728975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.
    Sorace AG; Saini R; Mahoney M; Hoyt K
    J Ultrasound Med; 2012 Oct; 31(10):1543-50. PubMed ID: 23011617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
    Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
    Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
    Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
    Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.